technetium tc-99m pentetate kit
Trade name: renotec
Small moleculeapprovedImaging agent
Approved
Feb 14, 1974
8-Hydroxyquinoline is an organic compound derived from the heterocycle quinoline. A colorless solid, its conjugate base is a chelating agent, which is used for the quantitative determination of metal ions. — Wikipedia
Clinical trial activity
8 trials · 6 clinical orgs · 5 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
3
Earliest trial started Feb 13, 2007 (NCT00426361)
Timeline
1970s
- Feb 14, 1974
Earliest FDA Approval
- Feb 14, 1974
General Electric — NDA Secondary Org
- Jul 8, 1974
Bracco — First NDA Organization
- Jul 8, 1974
Bracco — NDA Organization
- Nov 16, 1976
Jubilant DraxImage Inc. — NDA Secondary Org
1980s
- Dec 29, 1989
Jubilant DraxImage Inc. — Marketing Organization
2010s
- Jul 25, 2018
BWXT — Marketing Organization
2020s
- Mar 26, 2025
Curium Pharma — Marketing Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
Approval history
- approvedFeb 14, 1974
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O- Mol. weight
- 547.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 99-technetium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2110573 ↗
- Wikipedia8-Hydroxyquinoline ↗
- ChEMBLCHEMBL780 ↗
- ChEMBLCHEMBL2109916 ↗
- ChEMBLCHEMBL2096656 ↗
- ChEMBLCHEMBL1200452 ↗
Also known as
- (111in)oxinate(3)
- 111in-oxine
- dtpa
- dtpa
- dtpa
- human serum albumin diethylenetriaminepentaacetic acid technetium (99mtc) injection
- in-111 oxyquinoline
- in-111 oxyquinoline
- indium (111 in) oxyquinoline
- indium (111 in) oxyquinoline
- indium 111in oxyquinoline
- indium 111in oxyquinoline
- indium-111in, tris(8-quinolinolato-n1,o8)-
- indium-111 oxine
- indium-111 oxine
- indium-111-oxine
- indium-111-oxine sulfate
- indium-111 oxyquinoline
- indium-111 oxyquinoline
- indium (in111) oxine
- indium (in111) oxine
- indium in-111 oxine
- indium in-111 oxine
- indium in111 oxine
- indium in111 oxine
- indium (in111) oxyquinoline
- indium (in111) oxyquinoline
- indium in 111 oxyquinoline
- indium in 111 oxyquinoline
- indium in 111 oxyquinoline
- indium in-111 oxyquinoline
- indium in-111 oxyquinoline
- indium in-111 oxyquinoline
- indium in-111 oxyquinoline
- indium oxinate
- indium oxine
- indium oxine
- indium oxine
- indium oxine, 111in-labeled cpd
- indium oxine, 113in-labeled cpd
- indium oxine, 133in-labeled cpd
- indium oxine in 111
- indium oxine sulfate, 111in-labeled cpd
- indium oxyquinoline
- mpi dtpa kit - chelate
- mpi dtpa kit - chelate
- oxine
- oxine
- tc 99m dtpa kit (chelate)
- tc 99m dtpa kit (chelate)
- techneplex
- techneplex
- technetium (99mtc) pentetic acid
- technetium pentetate
- technetium tc 99m pentetate
- technetium tc 99m pentetate
- technetium tc-99m pentetate
- technetium tc-99m pentetate
- technetium tc-99m pentetate kit
- technetium tc-99m pentetate kit
- technetium tc-99m pentetate kit
- technetium tc-99m pentetate kit
- technetium tc-99m pentetate kit
- technetium tc 99m pentetate sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02145624 | Phase 4 | Oct 1, 2014 | National Institutes of Health (NIH), Public Health England, University of London |
| NCT01245049 | Phase 3 | Apr 1, 2011 | GlaxoSmithKline |
| NCT01027845 | Phase 3 | Dec 1, 2009 | GlaxoSmithKline |
| NCT01034514 | Early Phase 1 (Phase 1) | Dec 1, 2009 | Stanford University |
| NCT00871000 | Phase 3 | Apr 1, 2009 | GlaxoSmithKline |
| NCT00635128 | Phase 4 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00514059 | Phase 4 | Apr 1, 2007 | Government of Norway |
| NCT00426361 | Phase 3 | Feb 13, 2007 | GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2007 |
| Government of Norway | Government | 1 | 1 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2014 |
| Public Health England | Government | 1 | 1 | 1 | 2014 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| BWXT | For profit | MKTG | Jul 25, 2018 |
| Bracco | For profit | NDA | Jul 8, 1974 |
| Curium Pharma | For profit | MKTG | Mar 26, 2025 |
| General Electric | For profit | NDA2 | Feb 14, 1974 |
| Jubilant DraxImage Inc. | For profit | MKTG | Dec 29, 1989 |
| Jubilant DraxImage Inc. | For profit | NDA2 | Nov 16, 1976 |